Global Information, Inc. would like to present a new market research report, "The Antivirals Pipeline: Competitive Review" by Decision Resources, Inc..
Antiviral agents that treat diseases such as hepatitis C virus (HCV) and HIV can still expect success despite the already overcrowded market landscape. According to Decision Resources new report, "This potential for success is only one of the reasons that 122 companies are actively involved in clinical development of 139 antiviral agents despite the plethora of available agents." Although there are several obstacles challenging market growth, the antivirals market still represents an attractive market for drug developers due to the need for therapies that can deal with mutating viruses that render current therapies ineffective and a need for therapies that can treat the side effects that afflict patients on long-term antiviral therapy. The antivirals market has grown steadily since 2004. Continued steady growth is expected for this market with the exception of a less robust period between 2009 and 2010.
Questions addressed in this report:
- What market forces and trends are driving growth for the antivirals market? What situations will impact sales growth from 2009 to 2010?
- What are the various unmet needs in HIV, HCV, and other indicated diseases? How many antivirals are in development for HIV and HCV? How can these current therapies be classified?
- Which companies are the current leaders in the antivirals market? Which companies are projected to be the market leaders in 2015? Which companies are attempting to establish, grow, or protect their market position?
- Which indications and drug classes are projected to drive the majority of growth?